Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TNDM
SellHot AirTandem Diabetes Care, Inc. · Healthcare · United States · $1.5B · Avg Vol: $36M/d
COMPANY DESCRIPTION
Tandem Diabetes Care, Inc. is a medical device company focused on improving the lives of people with diabetes through innovative insulin pump technology. The company's t:slim X2 insulin pump with Control-IQ technology offers advanced automated insulin delivery, providing a significant competitive advantage in the personal diabetes management market. Its user-centric design and continuous innovation drive its market penetration and brand loyalty.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 801.2M | 747.7M | 940.2M | 1.0B | 8.2% | 1.0B | 1.1B | 1.2B | 9.0% |
| EPS | -1.47 | -3.43 | -1.47 | -3.04 | — | -0.90 | -0.67 | 0.17 | — |
| Shares | 64.5M | 65.6M | 66.3M | 68.3M | +5.9% | 69.6M | — | — | — |
| Debt | 419.9M | 415.7M | 473.6M | 444.5M | 1.9% | 739.3M | — | — | — |
| Equity | 439.9M | 313.6M | 263.1M | 155.2M | -29.3% | — | — | — | — |
| Op CF | 50.5M | -31.8M | 24.2M | -9.7M | -30.7% | -5.5M | — | — | — |
| Inv CF | 33.2M | -85.7M | -23.5M | 72.9M | — | — | — | — | — |
| Fin CF | 16.9M | 4.1M | 8.4M | -43.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TNDM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TNDM | Tandem Diabetes Care, Inc.(you) | $1.5B | 31 | Sell |
| ATEC | Alphatec Holdings, Inc. | $1.5B | 27 | Sell |
| AORT | Artivion, Inc. | $1.3B | 36 | Hold |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 28 | Sell |
| QDEL | QuidelOrtho Corporation | $1.0B | 29 | Sell |
| CBLL | CeriBell, Inc. | $911M | 27 | Sell |
| BBNX | Beta Bionics, Inc. | $887M | 27 | Sell |
| ENOV | Enovis Corporation | $1.4B | 45 | Hold |
| ESTA | Establishment Labs Holdings Inc. | $2.1B | 23 | Sell |
| TMDX | TransMedics Group, Inc. | $3.1B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%